Marianne T. Sweetser
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Amyloidosis: Diagnosis, Treatment, Outcomes, Porphyrin Metabolism and Disorders, Heme Oxygenase-1 and Carbon Monoxide, Multiple Sclerosis Research Studies, Neonatal Health and Biochemistry
Most-Cited Works
- → Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis(2018)2,831 cited
- → Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis(2012)1,686 cited
- → Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis(2012)1,322 cited
- → A Critical Role for Dnmt1 and DNA Methylation in T Cell Development, Function, and Survival(2001)1,268 cited
- → Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria(2020)572 cited
- → Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1(2021)476 cited
- → Antigen Presentation Pathways to Class I and Class II MHC‐Restricted T Lymphocytes(1987)322 cited
- → Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials(2010)284 cited
- → Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis(2023)275 cited
- → Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis(2015)262 cited